Zealand Pharma major shareholder announcement: Polar Capital
October 20 2023 - 3:00PM
Zealand Pharma major shareholder announcement: Polar Capital
Company announcement – No. 37 / 2023
Zealand Pharma major shareholder announcement: Polar
Capital
Copenhagen, Denmark, 20 October 2023 – Zealand
Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a
Copenhagen-based biotechnology company focused on the discovery and
development of innovative peptide-based medicines, today announces
the receipt on 20 October 2023 of notification pursuant to Section
38 of the Danish Capital Markets Act from the following major
shareholders:
As of 19 October 2023, Polar Capital LLP holds nominally
5,647,561 shares (each share carrying one vote) in Zealand Pharma
A/S, corresponding to 9.62% of the total share capital and total
voting rights in Zealand Pharma A/S.
Please see further details in the attached notification
form.
# # #
About Zealand Pharma A/SZealand Pharma A/S
(Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on
the discovery and development of peptide-based medicines. More than
10 drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. The company has
development partnerships with a number of blue-chip pharma
companies as well as commercial partnerships for its marketed
products.
Founded in 1998 and headquartered in Copenhagen, Denmark,
Zealand has a team in the U.S. For more information about Zealand’s
business and activities, please visit
http://www.zealandpharma.com.
Contact:
Anna Krassowska, PhD Vice President, Investor Relations &
Corporate Communications Zealand Pharma Email:
ank@zealandpharma.comAdam Lange Investor Relations OfficerZealand
Pharma Email: akl@zealandpharma.com |
- Zealand Pharma - Disclosure Form - 20.10.2023
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Sep 2023 to Sep 2024